07:17:02 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-13 Kvartalsrapport 2024-Q3
2024-08-07 Kvartalsrapport 2024-Q2
2024-05-24 Ordinarie utdelning PHO 0.00 NOK
2024-05-23 Årsstämma 2024
2024-05-15 Kvartalsrapport 2024-Q1
2024-02-21 Bokslutskommuniké 2023
2023-11-08 Kvartalsrapport 2023-Q3
2023-08-09 Kvartalsrapport 2023-Q2
2023-05-10 Kvartalsrapport 2023-Q1
2023-05-04 Ordinarie utdelning PHO 0.00 NOK
2023-05-03 Årsstämma 2023
2023-02-24 Bokslutskommuniké 2022
2023-02-23 Bokslutskommuniké 2022
2022-11-02 Kvartalsrapport 2022-Q3
2022-08-10 Kvartalsrapport 2022-Q2
2022-05-11 Kvartalsrapport 2022-Q1
2022-04-29 Ordinarie utdelning PHO 0.00 NOK
2022-04-28 Årsstämma 2022
2022-02-23 Bokslutskommuniké 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-08-11 Kvartalsrapport 2021-Q2
2021-07-28 Extra Bolagsstämma 2021
2021-05-21 Ordinarie utdelning PHO 0.00 NOK
2021-05-20 Årsstämma 2021
2021-05-19 Kvartalsrapport 2021-Q1
2021-03-03 Bokslutskommuniké 2020
2020-11-10 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-06-11 Ordinarie utdelning PHO 0.00 NOK
2020-06-10 Årsstämma 2020
2020-05-07 Kvartalsrapport 2020-Q1
2020-02-27 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-08-07 Kvartalsrapport 2019-Q2
2019-06-19 Extra Bolagsstämma 2019
2019-05-14 Kvartalsrapport 2019-Q1
2019-05-10 Ordinarie utdelning PHO 0.00 NOK
2019-05-09 Årsstämma 2019
2019-02-27 Bokslutskommuniké 2018
2018-11-08 Kvartalsrapport 2018-Q3
2018-08-08 Kvartalsrapport 2018-Q2
2018-05-23 Kvartalsrapport 2018-Q1
2018-05-11 Ordinarie utdelning PHO 0.00 NOK
2018-05-09 Årsstämma 2018
2018-02-27 Bokslutskommuniké 2017
2017-11-08 Kvartalsrapport 2017-Q3
2017-08-23 Kvartalsrapport 2017-Q2
2017-05-23 Kvartalsrapport 2017-Q1
2017-04-28 Ordinarie utdelning PHO 0.00 NOK
2017-04-27 Årsstämma 2017
2017-02-15 Bokslutskommuniké 2016
2016-11-15 Kvartalsrapport 2016-Q3
2016-08-23 Kvartalsrapport 2016-Q2
2016-05-10 Kvartalsrapport 2016-Q1
2016-04-29 Ordinarie utdelning PHO 0.00 NOK
2016-04-28 Årsstämma 2016
2016-02-11 Bokslutskommuniké 2015
2015-10-29 Kvartalsrapport 2015-Q3
2015-08-13 Kvartalsrapport 2015-Q2
2015-05-06 Kvartalsrapport 2015-Q1
2015-05-02 Ordinarie utdelning PHO 0.00 NOK
2015-04-30 Årsstämma 2015
2015-02-12 Bokslutskommuniké 2014
2014-11-06 Kvartalsrapport 2014-Q3
2014-08-26 Kvartalsrapport 2014-Q2
2014-05-28 Ordinarie utdelning PHO 0.00 NOK
2014-05-27 Årsstämma 2014
2014-05-07 Kvartalsrapport 2014-Q1
2014-02-27 Bokslutskommuniké 2013
2013-10-23 Kvartalsrapport 2013-Q3
2013-08-22 Kvartalsrapport 2013-Q2
2013-05-23 Ordinarie utdelning
2013-05-22 Årsstämma 2013
2013-04-25 Kvartalsrapport 2013-Q1
2013-02-28 Bokslutskommuniké 2012
2012-10-26 Kvartalsrapport 2012-Q3
2012-08-24 Kvartalsrapport 2012-Q2
2012-05-10 Årsstämma 2012
2012-04-26 Kvartalsrapport 2012-Q1
2012-02-16 Bokslutskommuniké 2011
2011-10-26 Kvartalsrapport 2011-Q3
2011-08-18 Kvartalsrapport 2011-Q2
2011-04-27 Kvartalsrapport 2011-Q1
2011-04-27 Årsstämma 2011
2011-02-17 Bokslutskommuniké 2010
2010-10-27 Kvartalsrapport 2010-Q3
2010-08-19 Kvartalsrapport 2010-Q2
2010-04-28 Kvartalsrapport 2010-Q1
2010-02-19 Bokslutskommuniké 2009
2009-11-26 Bonusutdelning

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriMedicinteknik
Photocure är verksamma inom medicinteknik. Bolaget specialiserar sig inom lösningar för fotodynamisk teknik. Idag används lösningarna för behandling av sjukdomar som föranlett cancer i urinblåsan och HPV. Huvudmarknaderna återfinns inom dermatologi och onkologi, där produkterna används av sjukhus och forskningsinstitut på global nivå. Bolaget grundades 1993 och har huvudkontor i Oslo, Norge.
2020-06-24 22:39:20
NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN
OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS,
ANY STATE OF THE UNITED STATES OF AMERICA AND THE DISTRICT OF COLUMBIA) (THE
"UNITED STATES"), AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION
OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH
THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

Oslo, Norway, 24 June 2020: Reference is made to the stock exchange notice
earlier today where Photocure ASA ("Photocure" or the "Company") announced the
launch of a private placement of new shares ("Offer Shares") in the Company (the
"Private Placement"). The Company is pleased to announce that it has allocated
2,500,000 shares at a subscription price of NOK 76 per share, raising gross
proceeds of NOK 190 million.

The subscription price was determined through an accelerated bookbuilding
process after close of trading on 24 June 2020. The Private Placement attracted
very strong interest from existing shareholders, as well as from new high
quality institutional investors. The Private Placement was multiple times
oversubscribed.

The Company intends to use the net proceeds from the Private Placement  (i.e.
net of transaction costs and employer's contributions triggered by the option
exercise) to i) create and scale up a world-class marketing, sales, and
distribution infrastructure after transfer of the business previously owned and
managed by Ipsen; ii) finance growth and working capital, including expansion in
underserved countries and new geographies currently not served by Photocure or
Ipsen; iii) explore new product opportunities / development, and new geographies
for Hexvix/Cysview to expand and secure its market position; and iv) general
corporate purposes.

The share capital increase of the Private Placement was resolved by the Board of
Directors of the Company (the "Board") on 24 June 2020 pursuant to an
authorization granted by the Company's general meeting held 10 June 2020.
Notification of allotment of the new shares in the Private Placement and payment
instructions will be sent to the applicants through a notification from the
Managers on 25 June 2020.

The Offer Shares is expected to be pre-funded by the Managers to facilitate a
swift registration of the share capital increase in the Norwegian Register of
Business Enterprises (the "NRBE") and delivery of the Offer Shares on a delivery
versus payment basis to the subscribers on or about 29 June 2020. The first day
of trading is expected to be on or about 26 June 2020, but not prior to the
share capital being registered in the NRBE, or prior to announcement by the
Company. Following registration of the new share capital pertaining to the
Private Placement, the Company will have a share capital of NOK 13,305,010.00
divided into 26,610,020 shares, each with a par value of NOK 0.50.

Radiumhospitalets Forskningsstiftelse, represented at the board by Anders Tuv,
has been allocated 26,300 new shares and will hold 679,619 shares in the
Company, corresponding to ~2.55% of the total outstanding shares following the
Private Placement.

The following primary insiders participated in the Private Placement:

  · Erik Dahl, CFO, has subscribed for 2,400 new shares and sold 24,000 new
shares pursuant to the terms of the employee share option program. Following
completion of the Private Placement, Erik Dahl holds, directly or indirectly,
13,033 shares in the Company.
  · Grete Hogstad, VP Strategic Marketing, has subscribed for 2,400 new shares
and sold 24,000 new shares pursuant to the terms of the employee share option
program. Following completion of the Private Placement, Grete Hogstad holds,
directly or indirectly, 21,844 shares in the Company.
  · Gry Stensrud, VP Technical Development and Operation, has subscribed for
2,700 new shares and sold 27,000 new shares pursuant to the terms of the
employee share option program. Following completion of the Private Placement,
Gry Stensrud holds, directly or indirectly, 9,889 shares in the Company.
  · Espen Njåstein, former Head Nordic Cancer Commercial Operations, has
subscribed for 2,330 new shares and sold 23,300 new shares pursuant to the terms
of the employee share option program. Following completion of the Private
Placement, Espen Njåstein holds, directly or indirectly, 13,399 shares in the
Company.

ABG Sundal Collier ASA and DNB Markets, a part of DNB Bank ASA acted as Joint
Bookrunners (collectively referred to as the "Managers") in the Private
Placement. Advokatfirmaet Selmer AS is acting as legal adviser to Photocure ASA.

For further information, please contact:

Dan Schneider

President and CEO

Photocure ASA

Tel: + 1-609 759-6515

Email: ds@photocure.com

Erik Dahl

Chief Financial Officer

Tel: +47 450 55 000

Email: ed@photocure.no

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

About Photocure ASA

Photocure, The Bladder Cancer Company, delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, which makes
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). The US headquarters for Photocure Inc., are in
Princeton, New Jersey. For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com

Important information

This announcement does not constitute or form a part of any offer of securities
for sale or a solicitation of an offer to purchase securities of the Company in
the United States or any other jurisdiction. The distribution of this
announcement and other information may be restricted by law in certain
jurisdictions. Copies of this announcement are not being made and may not be
distributed or sent into any jurisdiction in which such distribution would be
unlawful or would require registration or other measures. Persons into whose
possession this announcement or such other information should come are required
to inform themselves about and to observe any such restrictions.

The securities of the Company may not be offered or sold in the United States
absent registration or an exemption from registration under the U.S. Securities
Act of 1933, as amended (the "U.S. Securities Act"). The securities of the
Company have not been, and will not be, registered under the U.S. Securities
Act. Any sale in the United States of the securities mentioned in this
communication will be made solely to "qualified institutional buyers" as defined
in Rule 144A under the U.S. Securities Act. No public offering of the securities
will be made in the United States.

In any EEA Member State, this communication is only addressed to and is only
directed at qualified investors in that Member State within the meaning of the
EU Prospectus Regulation, i.e., only to investors who can receive the offer
without an approved prospectus in such EEA Member State. The expression "EU
Prospectus Regulation" means Regulation (EU) 2017/1129 of the European
Parliament and of the Council of 14 June 2017 (together with any applicable
implementing measures in any Member State).

In the United Kingdom, this communication is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the "Order") or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred to
as "Relevant Persons"). These materials are directed only at Relevant Persons
and must not be acted on or relied on by persons who are not Relevant Persons.
Any investment or investment activity to which this announcement relates is
available only to Relevant Persons and will be engaged in only with Relevant
Persons. Persons distributing this communication must satisfy themselves that it
is lawful to do so.

Any Target Market Assessment is without prejudice to the requirements of any
contractual, legal or regulatory selling restrictions in relation to the
Offering.

For the avoidance of doubt, the Target Market Assessment does not constitute:
(a) an assessment of suitability or appropriateness for the purposes of MiFID
II; or (b) a recommendation to any investor or group of investors to invest in,
or purchase, or take any other action whatsoever with respect to the Company's
shares.

Each distributor is responsible for undertaking its own Target Market Assessment
in respect of the Company's shares and determining appropriate distribution
channels.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as "anticipate", "believe",
"continue", "estimate", "expect", "intends", "may", "should", "will" and similar
expressions. The forward-looking statements in this release are based upon
various assumptions, many of which are based, in turn, upon further assumptions.
Although the Company believes that these assumptions were reasonable when made,
these assumptions are inherently subject to significant known and unknown risks,
uncertainties, contingencies and other important factors which are difficult or
impossible to predict and are beyond its control. Such risks, uncertainties,
contingencies and other important factors could cause actual events to differ
materially from the expectations expressed or implied in this release by such
forward-looking statements.

Actual events may differ significantly from any anticipated development due to a
number of factors, including without limitation, changes in investment levels
and need for the Company's services, changes in the general economic, political
and market conditions in the markets in which the Company operate, the Company's
ability to attract, retain and motivate qualified personnel, changes in the
Company's ability to engage in commercially acceptable acquisitions and
strategic investments, and changes in laws and regulation and the potential
impact of legal proceedings and actions. Such risks, uncertainties,
contingencies and other important factors could cause actual events to differ
materially from the expectations expressed or implied in this release by such
forward-looking statements. The Company does not provide any guarantees that the
assumptions underlying the forward-looking statements in this announcement are
free from errors nor does it accept any responsibility for the future accuracy
of the opinions expressed in this announcement or any obligation to update or
revise the statements in this announcement to reflect subsequent events. You
should not place undue reliance on the forward-looking statements in this
document. Current market conditions are affected by the COVID-19 virus outbreak.
The development in both Photocure's operations as well as relevant financial
markets in general may affected by government measures to mitigate the effect of
the virus, reduction in activity, unavailable financial markets and other. See
OSE notification of 7 April 2020 for an in-depth analysis of risk and effects of
the COVID-19 situation.

The information, opinions and forward-looking statements contained in this
announcement speak only as at its date, and are subject to change without
notice. Each of the Company, the Managers and their respective affiliates
expressly disclaims any obligation or undertaking to update, review or revise
any statement contained in this announcement whether as a result of new
information, future developments or otherwise.

This announcement is made by and, and is the responsibility of, the Company. The
Managers are acting exclusively for the Company and no one else and will not be
responsible to anyone other than the Company for providing the protections
afforded to their respective clients, or for advice in relation to the contents
of this announcement or any of the matters referred to herein.

Neither the Managers nor any of their respective affiliates makes any
representation as to the accuracy or completeness of this announcement and none
of them accepts any responsibility for the contents of this announcement or any
matters referred to herein.

This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company. Neither the
Managers nor any of their respective affiliates accepts any liability arising
from the use of this announcement.